MCRT Webcast: Making Sense of Myeloma Bone Issues - October 10, 2020

Name: MCRT Webcast: Making Sense of Myeloma Bone Issues - October 10, 2020
Start: 2020-10-10T09:00:00-06:00
End: 2020-10-10T15:00:00-06:00

Oct 10, 2020

09:00AM - 03:00PM MDT

Online Event

Overview

Bone pain is often the first symptom myeloma patients experience—often before they have been diagnosed—because bone degeneration is one of the most common effects of the disease. The bone strengthening class of drugs, bisphosphonates, was pioneered in myeloma treatment and is now of the most prescribed drug therapies for all cancer patients. Eliminating and lessening the potential of fractures and pain is an essential goal of treatment. Additionally, new therapies including genetically-targeted medicines are now being integrated into patient care.

Drs. Morie Gertz and Noopur Raje explain what patients need to understand about bone disease management and treatment in the Myeloma Crowd Round Table Interactive Webcast on October 10, 2020.

Thanks to our Round Table sponsors

User uploaded media

Highlights

Agenda

09:00 AM

Round Table

Drs. Morie Gertz and Noopur Raje

Speakers & Moderators

Morie Gertz, MD, MACP

Morie Gertz, MD, MACP, is the Roland Seidler, Jr. Professor of the Art of Medicine and Chair of the Department of Medicine at the Mayo Clinic in Rochester, MN. He is board certified in Internal Medicine, Hematology and Medical Oncology. Dr. Gertz has also served as Treasurer of the International Myeloma Society and President of Mayo Staff Officers and Councilors. He was the Chair of the Mayo Personnel Committee. Currently he serves on the American Society of Hematology Training Program Committee and the American Board of Internal Medicine Hematology Board Exam Committee. Dr. Gertz has been recognized with the 2014 Jan Waldenström Medal for Medical and Scientific Achievements in Waldenström Macroglobulinemia and is a Mayo Distinguished Clinician. He has been recognized for his contributions in amyloidosis and Waldenström macroglobulinemia, has authored more than five hundred peer-reviewed publications, and is a master of the America College of Physicians. He graduated from Northwestern University with highest distinction as a Phi Beta Kappa and received his medical degree cum laude from Loyola Medical School and was elected to Alpha Omega Alpha, the medical honor society. He completed a three-year medical residency at Rush Presbyterian St. Luke’s Hospital in Chicago and was twice voted Resident of the Year.

Noopur Raje, MD

Noopur Raje, MD, is director of the Center for Multiple Myeloma at Massachusetts General Hospital. She is also Associate Professor of Medicine at Harvard Medical School. Her primary focus is treating patients with multiple myeloma and related plasma cell disorders. Dr. Raje leads a dedicated clinical team engaged in investigator-initiated, multi-center national and international clinical trials, all aimed at developing new promising therapies for multiple myeloma. Her laboratory efforts are focused on identifying cellular signaling pathways that contribute to the survival and proliferation of myeloma cells in the bone environment for which targeting may result in improved therapeutic outcomes.